✦ LIBER ✦

Cyproterone acetate–-mechanism of action and clinical effectiveness in prostate cancer treatment

✍ Scribed by F. H. Schröder

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 669 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19931215)72:12+<3810::aid-cncr2820721710>3.0.co;2-o

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of cyproterone/acetate (SH-714) o

Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer

✍ Holub, G. ;Lunglmayr, G. ;Spona, J. 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 218 KB

Plasma prolactin was measured in 10 patients with prostatic cancer during treatment with cyproterone acetate (300 mg/week i.m.) Prolactin was assayed during a six month period at weekly intervals during the first 4 weeks and then at monthly intervals. Orchiectomy was not carried out. After 6 months

Cyproterone acetate in the treatment of

Cyproterone acetate in the treatment of metastatic cancer of the male breast

✍ Massimo Lopez 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 3 views

Short-term versus long-term addition of

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer

✍ J. G. M. Klijn; H. J. De Voogt; U. E. Studer; F. H. Schröder; R. Sylvester; M. D 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB 👁 3 views

The effects of orchiectomy, oestrogens a

The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate

✍ Varenhorst, Eberhard ;Wallentin, Lars ;Risberg, Bo 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 341 KB

The incidence of thromboembolic complications is increased in patients with oestrogen-treated prostatic carcinoma. Because reduced antithrombin-III (AT-III) levels are associated with increased risk of thromboembolism we have determined AT-III concentrations during oestrogen therapy and other treatm

Luteinizing hormone-releasing hormone ag

Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol

✍ Nicholas Bruchovsky; S. Larry Goldenberg; Koichiro Akakura; Paul S. Rennie 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

Bicalutamide (Casodex®) in the treatment

Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

✍ Kolvenbag, Geert J.C.M.; Blackledge, George R.P.; Gotting-Smith, Karen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

BACKGROUND. Bicalutamide (Casodex) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate cancer have been evaluated in randomized clinical tria